Esperion Therapeutics
ESPR
NASDAQ
IPO2013
about ESPR
Esperion Therapeutics develops oral medications designed to lower LDL cholesterol, targeting patients with high cholesterol or those who cannot tolerate statins.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $2.67 | $3.06 | $2.63 | $650.25M | 7.41M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.16 | n/a | n/a | -11.41% | -35.89% | 0% |